SCHEMBL197183

SCHEMBL197183

CC(C)NC(=O)C(O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.58
NFE2L2 Q16236 1/20 0.58
LMNA P02545 4/20 0.54
MAPK1 P28482 1/20 0.54
NAAA Q02083 2/20 0.50
PSMB5 P28074 1/20 0.50
HPGD P15428 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.47
THRB P10828 1/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197182 1.00 KEAP1 (0.58) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL8974575 0.86 MEN1 (0.64) KEAP1NFE2L2LMNAMAPK1HPGD
SCHEMBL28408400 0.86 MEN1 (0.64) KEAP1NFE2L2LMNAMAPK1HPGD
SCHEMBL15743807 0.83 KEAP1 (0.54) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL27896435 0.82 KEAP1 (0.52) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL27478055 0.82 KEAP1 (0.52) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL5843204 0.82 KEAP1 (0.52) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL5843192 0.82 KEAP1 (0.52) KEAP1NFE2L2LMNAMAPK1NAAA
SCHEMBL24757742 0.82 HDAC3 (0.61) LMNAMEN1KMT2AALDH1A1GAA
SCHEMBL18885406 0.82 GPR88 (0.53) LMNAMEN1KMT2ATHRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0098743-B1 PHENYL ALPHA-ACYLOXYACETAMIDE DERIVATES AND THEIR THERAPEUTIC USE Yu, Ruey J., Dr. (US) 1988-09-28 EP claimed
CN-112142663-B Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline 中山奕安泰医药科技有限公司 2022-03-22 CN disclosed
CN-112250533-B Synthesis method of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine 中山奕安泰医药科技有限公司 2022-03-22 CN disclosed
CN-112250533-A Synthesis method of (S) -1- (3-ethoxy-4-methoxyphenyl) -2- (methylsulfonyl) ethylamine 中山奕安泰医药科技有限公司 2021-01-22 CN disclosed
CN-112142663-A Synthesis method of (S) -1-phenyl-1, 2,3, 4-tetrahydroisoquinoline 中山奕安泰医药科技有限公司 2020-12-29 CN disclosed
EP-2402322-A1 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist Actelion Pharmaceuticals Ltd. (CH) 2012-01-04 EP disclosed
US-20110028509-A1 Sulfonamides MERCK SERONO SA (CH) 2011-02-03 US disclosed
EP-0098743-B1 PHENYL ALPHA-ACYLOXYACETAMIDE DERIVATES AND THEIR THERAPEUTIC USE Yu, Ruey J., Dr. (US) 1988-09-28 EP disclosed
US-4518789-A Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use YU RUEY J 1985-05-21 US disclosed
EP-0098743-A1 Phenyl alpha-acyloxyacetamide derivates and their therapeutic use Yu, Ruey J., Dr. (US) 1984-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028509-A1 Sulfonamides CXCR3, CXCR2, CXCR1 KEAP1 1585/4885NFE2L2 2889/4885LMNA 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.